Coverage
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets as it navigates a period of strategic and leadership transition.
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets, and forecast a similar performance for the year ahead as it implements a new strategy.
Coloplast interim Chief Executive Lars Rasmussen will step down from the company's board of directors, the latest leadership change at the Danish medical device maker as it implements a new strategy.
Danish medical device maker Coloplast on Tuesday unveiled a new five-year strategy that tempers its long-term growth forecast.
Danish medical device maker Coloplast on Tuesday tempered its long-term growth forecast as it unveiled a new five-year strategy, dubbed "Impact4."
Danish medical device maker Coloplast announced a significant overhaul of its executive team and corporate structure on Tuesday, moves it said are designed to support a new long-term strategy.
Filings
| Filing | Date |
|---|---|
| Share buy-back week 23/2019 | 11 Jun 2019 |
| Coloplast announcement no. 05/2019 - Comment on market rumours | 4 Jun 2019 |
| Share buy-back week 22/2019 | 3 Jun 2019 |
| Share buy-back week 21/2019 | 27 May 2019 |
| Share buy-back week 20/2019 | 20 May 2019 |
| Coloplast share buy-back week 19/2019 | 13 May 2019 |
| Share buy-back week 18/2019 | 6 May 2019 |
| Coloplast announcement no. 04/2019 - Interim Financial Report, H1 2018/19 | 2 May 2019 |
| Coloplast continues solid performance in Q2 and raises expectations for reported growth in DKK | 2 May 2019 |
| Coloplast announcement no. 04/2019 - Interim Financial Report, H1 2018/19 | 2 May 2019 |
| Share buy-back week 17/2019 | 29 Apr 2019 |
| Share buy-back week 16/2019 | 23 Apr 2019 |